Radiation Oncology

HER+

Questions discussed in this category

What are your top takeaways in Breast Cancer from ESMO 2025?

7 Answers available

Papers discussed in this category

Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Oct 18

Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial.

The New England journal of medicine, 2025 Oct 19

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.

Future oncology (London, England), 2023 Aug 01

TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.

J. Clin. Oncol., 2020 Sep 20

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).

The New England journal of medicine, 2024 Mar 21

Ribociclib plus Endocrine Therapy in Early Breast Cancer.

The New England journal of medicine, 2025 May 31

Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.

The New England journal of medicine, 2025 Oct 29

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.

Related Topics in Radiation Oncology